Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.